Study summary · research use only
Heparin Oligosaccharides as Vasoactive Intestinal Peptide Inhibitors via their Binding Process Characterization
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This study used PC3 human prostate cancer cells and biochemical/biophysical assays (GMSA, ITC, NMR, molecular docking, ELISA) to characterize the binding process between heparin oligosaccharides and vasoactive intestinal peptide (VIP), which the authors describe as competitively blocking VIP's binding to its receptor. Heparin oligosaccharides were produced by enzymatic digestion and purification, and their structures characterized by NMR. The abstract reports that both the length and sulfation pattern of heparin oligosaccharides affected binding to VIP, and that VIP induced higher cAMP expression in PC3 cells, an effect that could be regulated by heparin oligosaccharide binding. The authors describe non-anticoagulant heparin oligosaccharides as blocking the VIP-mediated cAMP/PKA signaling pathway, which they associate with the compounds' antitumor activity in this system.
Abstract
It has been proven that vasoactive intestinal peptide (VIP) was involved in the pathogenesis of prostate cancer. Cardin et al. found that by an alanine scan, the heparin- binding site on VIP was exactly the same sequence in VIP and its receptor. Therefore, heparin could competitively block the binding of VIP and its receptor. However, the structure-activity relationship between heparin and VIP has not been reported, especially in terms of the sequence and sulfation patterns of heparin oligosaccharides upon binding to VIP. A variety of experiments were designed to study the binding process and structure-activity relationship between heparin oligosaccharides and VIP. Heparin was enzymatically digested and purified to produce heparin oligosaccharides, and the structures were characterized by NMR. The binding capacity between heparin oligosaccharides and VIP was analyzed by GMSA and ITC experiments. The binding between heparin oligosaccharides and VIP was simulated using a molecular docking program to show the complex. ELISA assay was used to investigate the effect of non-anticoagulant heparin oligosaccharides on the VIP-mediated cAMP/PKA signaling pathway in vitro. The results indicated that both the length and the sulfation pattern of heparin oligosaccharides affected its binding to VIP. VIP could induce the expression of cAMP at a higher level in PC3 cells, which could be regulated by the interaction of heparin oligosaccharides and VIP. The binding between heparin oligosaccharides and VIP could block the binding between VIP and its receptor on tumor cells. Downloading the regulation of the expression level of cAMP could possibly further affect the subsequent activation of PKA. These non-anticoagulant heparin oligosaccharides may block the VIP-mediated cAMP/PKA signaling pathway and thus exert their antitumor activity.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.